Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Huntington: The Neurodegenerative, Hyperkinetic, and Neuropsychiatric Disease

Huntington: The Neurodegenerative, Hyperkinetic, and Neuropsychiatric Disease

Fymat, Alain L.

Paperback

Health GeneralPain Management

ISBN10: 1779626584
ISBN13: 9781779626585
Publisher: Tellwell Talent
Published: Dec 21 2024
Pages: 570
Weight: 3.88
Height: 1.55 Width: 8.50 Depth: 11.00
Language: English

Huntington's disease is a rare inherited, progressive, incurable, and fatal neurodegenerative disorder of the central nervous system. It affects muscle function and further leads to cognitive decline and dementia. It can present at any time in people during their life span. Symptoms may vary from person to person and usually appear in people who are in their 30s or 40s, but also earlier in life and even in children younger than 10. Most symptoms can be classified under motor, behavioral, or cognitive categories. The disease is caused by a defective gene characterized by an excessive number of trinucleotide (Cystosine-Adenine-Guanine) repeats - a part of the DNA code. The gene produces a protein of unknown function named Huntingtin, which is involved in the functioning of the nerve cells in the brain (neurons). When defective, the gene produces an abnormal (or mutated) Huntingtin protein that is toxic and causes selective loss of neurons. The pathogenesis of the disease remains, however, largely unclear so that the exact cause of neuronal death is unknown. Since each patient may have a unique combination of symptoms, there is no standardized treatment so that medication is prescribed on a case-by-case basis. Pharmacotherapy includes chorea medication, antipsychotics, antidepressants, mood-stabilizing medication as well as non-drug therapies. Side effects from medications can also affect each patient differently. Notwithstanding such approved therapies for specific disease symptoms, there is currently no cure and there are no approved drugs that delay the onset or slow disease progression. Fortunately, there are also many new therapeutics currently undergoing clinical trials that target the disease at its origin by lowering the levels of the mutant Huntingtin protein. In this book, I discuss the disease at length in its multiple facets and address the issue of its prevention and prognosis. I also consider what can be done about it and list the several available support and research organizations. Lastly, I review the current research and latest research developments in this subject.

1 different editions

Also available

Also from

Fymat, Alain L.

View All

Also in

Pain Management

View All